CDH13 and ovarian neoplasm: Clinically, CDH13 promoters are more heavily methylated in ovarian tumors than in normal tissue, and a DNA-methyltransferase inhibitor can reactivate CDH13 expression in cancer cells and its anti-tumor functions [121].